Back to News
Market Impact: 0.25
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
Source: globenewswire.com
Healthcare & Biotech
Paired-biopsy analysis from the randomized Phase 2 OVATION 2 study found that IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma. The report provides biomarker findings but no numerical effect sizes or clinical outcome data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
IMNN0.60
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Truist raises Vericel stock price target on MACI growth momentum
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)